About tofacitinib citrate equivalent to tofacitinib
Janus kinase (JAK) inhibitor
Used for
- Rheumatoid arthritis
- Psoriatic arthritis
- Ulcerative colitis
- Juvenile idiopathic arthritis
Usual adult dose
Usually 5 mg twice daily for arthritis; ulcerative colitis dosing varies by treatment phase and response.
Usual dose in children
For juvenile arthritis, usually 5 mg twice daily for children weighing at least 40 kg; lower weight-based doses apply below 40 kg.
Common side effects
- Infections, including shingles
- Headache
- Diarrhea
- Increased cholesterol or liver enzymes
Important warnings
- Can cause serious infections, including tuberculosis and opportunistic infections.
- May increase risks of blood clots, major cardiovascular events, cancer, and death.
- Avoid live vaccines; screening and monitoring are needed during treatment.
- Use with caution in older adults, smokers, and people with cardiovascular or clotting risks.
Pregnancy
May harm an unborn baby; pregnancy exposure should be discussed with a healthcare professional.
Breastfeeding
Breastfeeding is not recommended during treatment and for at least 18 hours after the last immediate-release dose.
Interactions
- Strong CYP3A4 inhibitors, such as ketoconazole, can raise tofacitinib levels.
- Strong CYP3A4 inducers, such as rifampin, can reduce its effect.
- Avoid combining with biologic immune-modifying medicines or potent immunosuppressants.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.